Compounds > amtizol
Page last updated: 2024-12-08

amtizol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

amtizol: used for recovery of consciousness after ketamine anesthesia; antihypoxic; a ketamine antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID161810
SCHEMBL ID6002314
MeSH IDM0129680

Synonyms (19)

Synonym
34283-30-2
amtizol
EU-0000373
STK368697
1,2,4-thiadiazole-3,5-diamine
AKOS001025781
3,5-diamino-1,2,4-thiadiazole
SCHEMBL6002314
1,2,4-thiadiazole, 3,5-diamino-
mfcd00159795
1,2,4-thiadiazole-3,5-diamine, aldrichcpr
F20081
Z56755595
5-amino-3-imino-1,2,4-thiadiazoline
EN300-106534
1,2,4-thiadiazolidine-3,5-diimine
DTXSID20955841
LS-06916
CS-0311959

Research Excerpts

Actions

ExcerptReferenceRelevance
"Amtizol was able to activate utilising of carbohydrates in a glycolytic way in satisfied rats with a blockade of glycolysis by monoiodacetate, whereas glyconeogenesis was activated in starving rats."( [The role of glycolysis in the protective effect of amtizol during acute hypoxia].
Krivoruchko, BI; Smirnov, AV; Zarubina, IV, 2000)		1.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (9.09)18.7374
1990's2 (18.18)18.2507
2000's2 (18.18)29.6817
2010's6 (54.55)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (96.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
succinic acid
Succinic Acid: A water-soluble, colorless crystal with an acid taste that is used as a chemical intermediate, in medicine, the manufacture of lacquers, and to make perfume esters. It is also used in foods as a sequestrant, buffer, and a neutralizing agent. (Hawley's Condensed Chemical Dictionary, 12th ed, p1099; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1851). succinic acid : An alpha,omega-dicarboxylic acid resulting from the formal oxidation of each of the terminal methyl groups of butane to the corresponding carboxy group. It is an intermediate metabolite in the citric acid cycle.		2.0710alpha,omega-dicarboxylic acid;
C4-dicarboxylic acid		anti-ulcer drug;
fundamental metabolite;
micronutrient;
nutraceutical;
radiation protective agent
ketamine
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.		1.9610cyclohexanones;
monochlorobenzenes;
secondary amino compound		analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic
6-methyl-2-ethyl-3-hydroxypyridine
6-methyl-2-ethyl-3-hydroxypyridine: compound used in second source was chlorhydrate; has been used as retinoprotector		2.0110
emoxypine succinate
emoxypine succinate: has antihypoxic effects		2.2110
guanylthiourea
Guanylthiourea: May protect against hypoxic damage; proposed for treatment of shock due to trauma or blood loss; also stimulates paretic gastrointestinal system.		2.4420
bemethyl
bemethyl: 2-mercaptobenzimidazole deriv.; alkylating agent and mutagen antagonist		2.0810
losartan potassium
Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.		2.1710
ConditionIndicatedRelationship StrengthStudiesTrials
Amnesia-Memory Loss
[description not available]		02.2110
Cerebral Ischemia
[description not available]		02.5720
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.5720
Amnesia
Pathologic partial or complete loss of the ability to recall past experiences (AMNESIA, RETROGRADE) or to form new memories (AMNESIA, ANTEROGRADE). This condition may be of organic or psychologic origin. Organic forms of amnesia are usually associated with dysfunction of the DIENCEPHALON or HIPPOCAMPUS. (From Adams et al., Principles of Neurology, 6th ed, pp426-7)		02.2110
Brain Ischemia
Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.		02.5720
Anoxemia
[description not available]		02.9840
Hypoxia
Sub-optimal OXYGEN levels in the ambient air of living organisms.		02.9840
Hypercapnia
A clinical manifestation of abnormal increase in the amount of carbon dioxide in arterial blood.		07.0810
Anoxia, Brain
[description not available]		02.0110
Arterial Obstructive Diseases
[description not available]		01.9610
Arterial Occlusive Diseases
Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency.		01.9610
Chronic Illness
[description not available]		01.9910
Cardiomyopathy, Congestive
[description not available]		01.9910
Cardiac Failure
[description not available]		01.9910
Heart Disease, Ischemic
[description not available]		01.9910
Bouillaud Disease
[description not available]		01.9910
Cardiomyopathy, Dilated
A form of CARDIAC MUSCLE disease that is characterized by ventricular dilation, VENTRICULAR DYSFUNCTION, and HEART FAILURE. Risk factors include SMOKING; ALCOHOL DRINKING; HYPERTENSION; INFECTION; PREGNANCY; and mutations in the LMNA gene encoding LAMIN TYPE A, a NUCLEAR LAMINA protein.		01.9910
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		01.9910
Heart Failure
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.		01.9910
Rheumatic Heart Disease
Cardiac manifestation of systemic rheumatological conditions, such as RHEUMATIC FEVER. Rheumatic heart disease can involve any part the heart, most often the HEART VALVES and the ENDOCARDIUM.		01.9910
Myocardial Ischemia
A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).		01.9910
Acute Disease
Disease having a short and relatively severe course.		0210